Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.

  • Revenue in EUR (TTM)18.39bn
  • Net income in EUR806.29m
  • Incorporated2006
  • Employees123.15k
  • Location
    Fresenius Medical Care AG & Co KGaAElse-Kroener-Strasse 1BAD HOMBURG VOR DER HOHE 61352GermanyDEU
  • Phone+49 61726090
  • Fax+49 61 726092301
  • Websitehttps://www.freseniusmedicalcare.com/
More ▼

Institutional shareholders

22.39%Per cent of shares held by top holders
HolderShares% Held
Harris Associates LPas of 10 Mar 202214.27m4.86%
Dodge & Coxas of 15 Feb 20228.83m3.01%
Pzena Investment Management LLCas of 20 Apr 20228.82m3.01%
Artisan Partners LPas of 12 Jul 20228.79m2.99%
Templeton Global Advisors Ltd.as of 30 Jun 20226.06m2.07%
The Vanguard Group, Inc.as of 05 Aug 20225.49m1.87%
Norges Bank Investment Managementas of 31 Dec 20213.99m1.36%
FIL Investment Advisors (UK) Ltd.as of 31 May 20223.53m1.20%
BlackRock Fund Advisorsas of 03 Aug 20223.51m1.20%
DWS Investment GmbHas of 04 Aug 20222.41m0.82%
More ▼
Data from 31 Dec 2021 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.